Joint Treatments for Performance Horses: What Each One Actually Does

Ask three trainers what to give a horse with a sore joint and you will get three different answers, all of them delivered with total confidence. The products involved — pentosan, chondroitin, hyaluronic acid, bisphosphonates, corticosteroid injections — are often discussed as if they were interchangeable strengths of the same thing. They are not. They act on completely different parts of the problem, and choosing between them starts with understanding what osteoarthritis actually is.

What is going wrong in the joint

A healthy joint is a low-friction system: cartilage covering the bone ends, synovial fluid lubricating the contact, and subchondral bone beneath absorbing load. Osteoarthritis is the progressive failure of that system, and it runs on three tracks at once.

Cartilage breaks down. Catabolic enzymes degrade the proteoglycan matrix faster than the joint can rebuild it. The surface roughens, thins and loses its ability to distribute load.

Synovial fluid degrades. Inflamed synovium produces fluid that is thinner and less viscous. Lubrication drops, which increases mechanical wear, which increases inflammation.

Subchondral bone changes. The bone beneath the cartilage remodels under repeated concussion. Microfractures, sclerosis and impaired blood flow follow, and the pain from this layer can be as significant as the pain from the cartilage above it.

This matters because an intervention that addresses one track leaves the other two running.

Pentosan polysulfate: the disease-modifying end

Pentosan polysulfate sodium is a semi-synthetic polysulfated xylan derived from beech wood hemicellulose. It is classed as a disease-modifying osteoarthritis drug, and it is one of the few products in this field that acts on the joint environment rather than on pain perception.

It works on several fronts simultaneously: it stimulates the synovial membrane to produce hyaluronic acid and proteoglycans, restoring viscosity to the joint fluid; it inhibits the catabolic enzymes that degrade cartilage matrix; and it improves blood flow through the subchondral bone by reducing fibrin deposits in small vessels. In other words, it touches all three tracks.

An injectable pentosan product received FDA approval in December 2022 for the control of clinical signs associated with osteoarthritis in horses — the first injectable pentosan to meet FDA standards for safety, efficacy and consistent manufacturing.

One caution that gets overlooked: pentosan polysulfate has anticoagulant properties. It is not suitable for animals with clotting disorders, active bleeding, or those facing surgery.

Chondroitin sulphate and hyaluronic acid: rebuilding the matrix and the fluid

Chondroitin sulphate is a structural component of cartilage matrix itself. Injectable chondroitin preparations aim to supply substrate for matrix repair and to inhibit degradative enzymes. They sit on the cartilage track specifically.

Hyaluronic acid addresses the fluid track. It is the molecule that gives synovial fluid its viscosity, and in an inflamed joint its concentration and molecular weight both fall. Supplementing it — whether intra-articularly or intravenously — aims to restore lubrication and reduce the mechanical component of the damage cycle.

Neither is a painkiller. A horse given chondroitin on Monday is not more comfortable on Tuesday, and owners who expect that conclude the product does not work. These are slow-acting agents whose value is measured over weeks and in the joint’s trajectory rather than in next week’s performance.

Bisphosphonates: the bone track

Bisphosphonates such as clodronate and zoledronic acid act on bone, not cartilage. They inhibit osteoclasts — the cells that resorb bone — and so slow the remodelling that drives subchondral pain. Clodronate disodium is licensed for the control of clinical signs associated with navicular syndrome in horses, a condition in which the bone component dominates.

These are not general-purpose joint products. They are a targeted tool for conditions where the pathology sits in bone, and their use in young or still-growing animals is a subject of ongoing veterinary debate. This is a class where the decision genuinely belongs to the veterinarian.

Corticosteroid injections: fast, effective, and easy to overuse

Intra-articular corticosteroids — triamcinolone acetonide and methylprednisolone acetate being the common choices — suppress joint inflammation directly and quickly. When a joint is acutely inflamed and the horse is lame, nothing else in this list works as fast.

Triamcinolone acetonide is considerably more potent than the parent molecule, with roughly six to seven times the anti-inflammatory activity of prednisolone and slightly more than dexamethasone, and the acetonide group gives it sustained action.

The trade-offs are real and worth stating plainly. Repeated intra-articular corticosteroid administration is associated with cartilage damage over time. Systemic absorption from intrasynovial injection is greater than from extrasynovial sites and can produce hyperglycaemia, hyperinsulinaemia and suppression of the hypothalamic-pituitary-adrenal axis — which is why the laminitis risk attached to corticosteroids in susceptible horses is taken seriously. And because they suppress inflammation so effectively, they can mask a problem that is still progressing underneath.

Used at intervals, in the right joint, with an accurate diagnosis, they are one of the most useful tools in equine practice. Used monthly in a joint nobody has imaged, they buy short-term comfort at the cost of the joint.

How the pieces fit

A reasonable way to think about it:

• Acute flare, horse lame now — the anti-inflammatory end of the range, whether systemic or intra-articular, to break the inflammation cycle.
• Ongoing degenerative change — the disease-modifying agents, given as a course and judged over weeks.
• Pain localised to bone — bisphosphonates, on veterinary assessment.
• Every case — the unglamorous parts: surface quality, shoeing and foot balance, workload management, body weight, and honest rest.

These are not competing options so much as different layers, and in practice they are frequently combined. What does not work is picking one product because it worked for a stablemate with a different problem.

Diagnosis comes first, always

“Sore joint” is a symptom, not a diagnosis. Whether the pain sits in cartilage, in synovium, in subchondral bone or in soft tissue around the joint determines which of these categories is worth the money — and that question is answered by lameness examination and imaging, not by a product label.

It is also worth knowing the competition rules before you start. Corticosteroids and several of the other agents discussed here are controlled or prohibited substances under most racing and competition regulations, with defined detection times that differ by jurisdiction and by product.

This article is general information about a group of treatments, not veterinary advice, a diagnosis or a treatment plan. Product choice, route of administration, dose and treatment interval must be determined by the veterinarian attending the individual animal.